Reversible acute fetal renal failure due to maternal exposure to angiotensin receptor blocker.
We report on a case of fetal toxicity due to maternal treatment with olmesartan medoxomil. At 29 weeks' gestation, oligohydramnios was found, although the fetus had normal kidneys on ultrasound evaluation. Withdrawal of olmesartan medoxomil, maternal rehydration, and a single dose of furosemide reversed the renal impairment. After term delivery, the neonate was confirmed to have normal renal function. The case suggested that fetal renal impairment due to olmesartan medoxomil may be reversible.
Celentano
Claudio
C
Department of Obstetrics and Gynecology, University of Chieti, Via Sandro Pertini, 4, 65129, Pescara, Italy. ccelen@tin.it
Prefumo
Federico
F
di Vera
Elena
E
Iannicco
Annamaria
A
Gallo
Davide Pio
DP
Liberati
Marco
M
D047228:Angiotensin II Type 1 Receptor Blockers / Q000009:adverse effects*; D004232:Diuretics / Q000627:therapeutic use; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D005665:Furosemide / Q000627:therapeutic use; D005865:Gestational Age; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D007231:Infant, Newborn; D008297:Male; D018811:Maternal Exposure / Q000009:adverse effects*; D016104:Oligohydramnios / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D000068557:Olmesartan Medoxomil; D011247:Pregnancy; D011296:Prenatal Diagnosis; D020127:Recovery of Function; D051437:Renal Insufficiency / Q000139:chemically induced* / Q000188:drug therapy / Q000503:physiopathology; D013777:Tetrazoles / Q000009:adverse effects*; D016896:Treatment Outcome
D047228:Angiotensin II Type 1 Receptor Blockers; D004232:Diuretics; D007093:Imidazoles; D013777:Tetrazoles; D000068557:Olmesartan Medoxomil; D005665:Furosemide